Ben Ittensohn in high demand Paddington which was the only Brisbane suburb realestate.com.au expected to go back into the million-dollar median list by January.THESE three Queensland suburbs are housing the state’s next property millionaires, according to data crunched by realestate.com.au.According to realestate.com.au analysis of CoreLogic trends over the last three years, the next suburbs to cross the million-dollar median line mark a large triangle stretching from Central Queensland through to the New South Wales border and the capital city.For its sure bets to hit $1m median house prices in the next six months, REA backed Paddington in inner Brisbane, Castle Hill in Townsville and Tallebudgera in the southmost part of the Gold Coast.The first to cross the line to $1m was Townsville’s premier suburb, Castle Hill, which was expected to hit a seven digit median within the next two or so weeks.Its current median price was $950,000 with the forecast that it would be $1,040,105 in November.WEEKEND: Queenslanders galore on auction listBORROWING: Bank tightens loans on 91 suburbsTAX: Developers will be made to pay moreREA chief economist Nerida Conisbee said Townsville was starting to see a recovery from the mining downturn, which was “hitting premium suburbs first”.“This will likely extend to other suburbs over the next few years,” she said.Paddington in inner Brisbane, which was currently sitting on a median price just 2,000 below $1m, was expected to hit $1m in the new year. REA’s forecast was that Paddington would go to $1,000,452 in January.“In Brisbane, a million dollars still means something and you can still buy premium property in inner areas like Paddington,” Ms Conisbee said.More from newsParks and wildlife the new lust-haves post coronavirus1 day agoNoosa’s best beachfront penthouse is about to hit the market1 day agoThe third area expected to go off – Tallebudgera on the NSW-Queensland border – was currently sitting on $917,750, with a million-dollar date set for January too. REA expected it to go to a median of $1,015,569 in about 10 weeks.“We’re constantly seeing high levels of demand for Gold Coast – more people from Sydney are turning to Gold Coast for affordable lifestyle options.”That’s all good news for Ben Ittensohn, 38, who has lived in Paddington since he was 21 and was now bringing up his children there.“I think it will always be on a trajectory for growth because of its proximity to city,” he said. “Relative to other cities like Melbourne and Sydney, it’s amazing we’re still talking about the million dollar mark.”Mr Ittensohn has two properties in the suburb, both of which he planned to hold on to long term.“The investment property is a unit and units are not doing too well right now but we are looking long term. In the short term though it always rents really easy,” he said.“We’d love to upgrade our house next year or in years to come. Does that mean we can stay in Paddington? I really hope so. Maybe we might have to push out to Bardon and other suburbs. We wouldn’t be able to afford to have three properties in Paddington.”The best thing about the suburb, he said, was the stroll to Suncorp stadium. “I’m a big Broncos fan and being close to Suncorp is great. It’s very handy walking distance to the stadium.”undefined
InternationalLifestyleNews FDA Investigating Whether Diabetes Drug Metformin Contains Probable Carcinogen by: – December 16, 2019 Share A drug often prescribed to diabetes patients is being investigated for traces of a probable carcinogen after it was recalled abroad, the US Food and drug administration said.Health officials are investigating whether Metformin sold in the US contains NDMA, a contaminant that has been linked to cancer, the FDA said in a news release.Testing will also look into whether the amount of NDMA in the drug is above the acceptable daily intake limit of 96 nanograms.The drug is used to control high blood sugar in patients with type 2 diabetes.The FDA told patients to continue to use Metformin while the investigation continues because there are no alternative medications that treat type 2 diabetes the same way.As part of our continuing investigation, the FDA is investigating whether Metformin in the US market contains NDMA impurity, and whether it is above the acceptable daily intake limit of 96 nanograms.Everyone is exposed to some level of NDMA, which is a common contaminant found in water and foods including cured and grilled meats, dairy products and vegetables, health officials said.The substance may increase the risk of cancer in people who are exposed to high levels over long periods of time.“A person taking a drug that contains NDMA at-or-below the acceptable daily intake limit every day for 70 years is not expected to have an increased risk of cancer,” the FDA said.Metformin drugs have been recalled in Singapore, and other regulatory agencies in Europe are also investigating the presence of the contaminant.“Based on the information we have available, the levels of NDMA seen outside the u.s. Are within the range that is naturally occurring in some foods and in water,” the FDA said.There have been no recalls of Metformin in the US.“The agency will also work with companies to test samples of Metformin sold in the US and will recommend recalls as appropriate if high levels of NDMA are found,” the FDA said. “if as part of our investigation, Metformin drugs are recalled, the FDA will provide timely updates to patients and health care professionals.”Earlier this year, CVS announced it will be taking Zantac and other Ranitidine heartburn drugs off its shelves after health officials said that the drug contains low levels of NDMA. Share Share 86 Views no discussions Tweet Sharing is caring!
Tonight sees the first leg of the first of this week’s playoffs, with Norway playing host to Hungary. Kick off in Oslo is at 7.45. Captain Robbie Keane, Daryl Murphy and Kevin Doyle are Martin O’Neill’s options up front, after Tipperary’s Shane Long was ruled out of tomorrow’s game. The squad will train this evening at Bilino Polje in Zenica and Keane says it’s a squad who are quietly confident. Meanwhile